drugset
drugset / Trial / NCT07463677

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07463677 ↗

Phase 2 Not yet recruiting 55 enrolled Sun Yat-sen University
Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study investigated the efficacy and safety of Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Timeline

Start
2026-03-15
Primary completion
2028-05-31
Completion
2029-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab β Monoclonal antibody 500 mg/m2 Intravenous
Subject Fulzerasib Small molecule — —
Subject Tunlametinib Small molecule 6 mg Oral
Subject Tunlametinib Small molecule 9 mg Oral
Subject Tunlametinib Small molecule 12 mg Oral

Indications

non-small cell lung carcinoma